Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver

Cell Transplant. 2003;12(6):563-8.


Recently a phase I clinical trial has been started in Italy to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT) by the AMC-bioartificial liver (AMC-BAL). The AMC-BAL is charged with 10 x 10(9) viable primary porcine hepatocytes isolated from a specified pathogen-free (SPF) pig. Here we report a patient with ALF due to acute HBV infection. This patient was treated for 35 h by two AMC-BAL treatments and was bridged to OLT. There was improvement of biochemical and clinical parameters during the treatment. No severe adverse events were observed during treatment and follow-up of 15 months after hospital discharge. Possible porcine endogenous retrovirus (PERV) activity could not be detected in the patient's blood or blood cells up to 12 months after treatment.

Publication types

  • Case Reports
  • Clinical Trial
  • Clinical Trial, Phase I
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Ammonia / blood
  • Animals
  • Bilirubin / blood
  • Female
  • Hepatitis B / surgery*
  • Hepatocytes / cytology
  • Hepatocytes / immunology
  • Hepatocytes / transplantation
  • Humans
  • Lactic Acid / blood
  • Liver Failure, Acute / surgery*
  • Liver Transplantation / instrumentation*
  • Liver Transplantation / methods*
  • Liver, Artificial / standards
  • Liver, Artificial / trends*
  • Prothrombin / metabolism
  • Retroviridae / immunology
  • Specific Pathogen-Free Organisms
  • Sus scrofa
  • Transaminases / blood
  • Treatment Outcome


  • Lactic Acid
  • Ammonia
  • Prothrombin
  • Transaminases
  • Bilirubin